Franciele Barbosa Trapp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Franciele Barbosa Trapp has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Brusius‐Facchin
Medical Genetics Service Hospital de Clínicas de Porto Alegre (HCPA) Porto Alegre Brazil
2 shared publications - Francyne Kubaski
Greenwood Genetic Center, Greenwood, SC, USA
2 shared publications - Roberto Giugliani
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Casa dos Raros, Porto Alegre, Brazil; Dasa Genômica, São Paulo, Brazil
2 shared publications - Alice Brinckmann Oliveira Netto
Universidade Federal do Rio Grande do Sul, Brazil; Hospital de Clinicas de Porto Alegre, Brazil; Instituto de Genética para Todos, Brazil
1 shared publication Ana Cecília Menezes
1 shared publication- Augusto César Cardoso-Dos-Santos
Ministério da Saúde, Brazil
1 shared publication
Latest Publications
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S69
Prenatal diagnosis of mucopolysaccharidosis type VI by analysis of the amniotic fluid supernatant in the mass spectrometry era
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S69
Prenatal diagnosis of mucopolysaccharidosis type VI by analysis of the amniotic fluid supernatant in the mass spectrometry era
- 22 November 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (3) , 760-767
Sanfilippo syndrome type B: Analysis of patients diagnosed by the MPS Brazil Network
Mucopolysaccharidosis type IIIB is a rare autosomal recessive disorder characterized by deficiency of the enzyme N‐acetyl‐alpha‐d‐glucosaminidase (NAGLU), caused by biallelic pathogenic variants in the NAGLU gene, which leads to storage of heparan sulfate and a series of clinical consequences which hallmark is neurodegeneration. In this study clinical, epidemiological, and biochemical data were obtained from MPS IIIB patients diagnosed from 2004–2019 by the MPS Brazil Network (“Rede MPS Brasil”), which was created with the goal to provide an easily accessible and comprehensive investigation of all MPS types. One hundred and ten MPS IIIB patients were diagnosed during this period. Mean age at diagnosis was 10.9 years. Patients were from all over Brazil, with a few from abroad, with a possible cluster of MPS IIIB identified in Ecuador. All patients had increased urinary levels of glycosaminoglycans and low NAGLU activity in blood. Main clinical symptoms reported at diagnosis were coarse facies and neurocognitive regression. The most common variant was p.Leu496Pro (30% of alleles). MPS IIIB seems to be relatively frequent in Brazil, but patients are diagnosed later than in other countries, and reasons for that probably include the limited awareness about the disease by health professionals and the difficulties to access diagnostic tests, factors that the MPS Brazil Network is trying to mitigate.
- 22 November 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (3) , 760-767
Sanfilippo syndrome type B: Analysis of patients diagnosed by the MPS Brazil Network
Mucopolysaccharidosis type IIIB is a rare autosomal recessive disorder characterized by deficiency of the enzyme N‐acetyl‐alpha‐d‐glucosaminidase (NAGLU), caused by biallelic pathogenic variants in the NAGLU gene, which leads to storage of heparan sulfate and a series of clinical consequences which hallmark is neurodegeneration. In this study clinical, epidemiological, and biochemical data were obtained from MPS IIIB patients diagnosed from 2004–2019 by the MPS Brazil Network (“Rede MPS Brasil”), which was created with the goal to provide an easily accessible and comprehensive investigation of all MPS types. One hundred and ten MPS IIIB patients were diagnosed during this period. Mean age at diagnosis was 10.9 years. Patients were from all over Brazil, with a few from abroad, with a possible cluster of MPS IIIB identified in Ecuador. All patients had increased urinary levels of glycosaminoglycans and low NAGLU activity in blood. Main clinical symptoms reported at diagnosis were coarse facies and neurocognitive regression. The most common variant was p.Leu496Pro (30% of alleles). MPS IIIB seems to be relatively frequent in Brazil, but patients are diagnosed later than in other countries, and reasons for that probably include the limited awareness about the disease by health professionals and the difficulties to access diagnostic tests, factors that the MPS Brazil Network is trying to mitigate.